TherapeuticsMD, Inc. is a pharmaceutical royalty company that generates revenue by licensing intellectual property and trademarks to third-party pharmaceutical organizations. The company transitioned from a women's healthcare product developer to a royalty model in December 2022 through a transaction with Mayne Pharma LLC. Under this agreement, TherapeuticsMD granted Mayne Pharma exclusive licenses to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamins sold under the BocaGreenMD and vitaMedMD brands in the United States and its territories. The company also assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. TherapeuticsMD receives milestone payments, minimum annual royalties, and sales-based royalties from Mayne Pharma for the commercialization of these products. The company's wholly owned subsidiaries include vitaMedMD, LLC and BocaGreenMD, Inc.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage therapeuticsmd.com
Sector Healthcare IR page therapeuticsmd.com/investors/therapeuticsmd-update-regarding-covid-19.php
Tags
pharmaceutical royalties, women's health, contraception, menopause, prenatal vitamins, intellectual property licensing, vitaMedMD, BocaGreenMD, BIJUVA, IMVEXXY, ANNOVERA, vitaMedMD LLC, BocaGreenMD Inc.
Press page —

Metrics

Valuation  
Market cap $ 23.495M
Market cap (USD) $ 23.495M
P/E 203.00
PEG —
P/BV 0.85
P/S 6.27
P/OCF 6.98
P/FCF 9.57
Dividend yield —
Turnover / mcap —
Returns  
ROE -2.1%
ROI -2.3%
ROIC -13.4%
Profit margin -18.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 3.022M 1.761M 300K 69.963M 86.951M 64.872M 49.647M 16.099M 16.778M 19.356M 20.143M 15.026M 8.776M 3.818M 2.088M — — — 1.005M 968.085K 576.162K 415.926K 315.328K 365.225K 369.369K 198.388K
Net profit -569K -2.181M -10.278M 111.997M -172.415M -183.524M -176.145M -132.617M -76.925M -89.875M -85.077M -54.217M -28.419M -35.12M -12.913M -2.867M -395.553K 170.542K 373.015K 289.887K 142.116K 94.109K 98.912K 61.535K 131.668K 12.43K
Free cash flow 2.454M 1.17M -23.081M 9.004M -142.727M -159.677M -168.148M -107.029M -76.217M -69.538M -79.209M -45.552M -20.809M -12.804M -4.995M — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 1.63 0.86 2.25 5.59 0.36 1.21 2.42 3.81 6.04 5.77 10.37 4.45 5.21 — — — — — — — — — — — — —
Price performance 12m 0.9 -0.62 -0.6 14.72 -0.71 -0.5 -0.36 -0.37 0.05 -0.44 1.33 -0.15 — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4.5M 4.33M 11.1M 24.4M 32.4M 36.2M — — — —
↳ YoY growth +47.6% -3.8% +155.6% +120.5% +32.7% +11.7%
↳ 5y CAGR +178.8% +48.1% +45.6% +62.5% +60.4% +51.7%
Borrowings, current (USD) — — — — — 188M — — — —
Borrowings, non-current (USD) — — 73.4M 195M 238M 0.00 — — — —
Lease liabilities (USD) — — 4.1M 10.6M 10.9M 9.42M 8.76M 8.01M 7.18M 6.1M
Cash and deposits (USD) 132M 127M 162M 161M 80.5M 65.1M 64.9M 4.33M 5.06M 7.48M
Intangible assets (USD) 2.41M 3.1M 4.09M 5.26M 5.25M 40.3M 6.94M 6.1M 4.32M 3.76M
Right-of-use assets (USD) — — 3.8M 10.1M 9.57M 8.23M 7.58M 6.87M 6.1M 5.29M
Net debt (borrowings + leases - cash) (USD) — — -84.1M 44.5M 168M 133M — — — —
Cash flow detail
Operating cash flow (USD) -69.1M -76.2M -107M -166M -159M -143M 9.36M -23.1M 1.17M 2.45M
Purchases of property, plant and equipment (USD) -396,154 -61,817 -217,040 -2.45M -207,073 -34,000 — — — —
Purchases of intangible assets (USD) -845,266 -765,291 -1.11M -1.44M -1.39M -2.19M -355,000 — — —
Change in receivables (cash effect) (USD) -3.98M 167,691 -6.95M -13.6M -8.2M -4.33M — — — —
Change in inventories (cash effect) (USD) -386,168 -409,037 -1.78M -8.59M -3.34M -711,000 — — — —
Change in payables (cash effect) (USD) 4.23M -3.26M 18.6M -3.56M 1.89M -750,000 -1.21M -2.14M 231,000 119,000
Interest paid (cash effect) (USD) — — -1.89M -17.8M -25.8M -25.1M -13.5M — — —
Income taxes paid (cash effect) (USD) — — — — — — — — -80,000 -36,000
Share-based compensation (USD) 17.4M 6.89M 8.66M 10.7M 10.7M 18.1M 11.6M 1.27M 264,000 75,000
Operating cash flow before change in receivables (USD) -65.2M -76.3M -99.9M -152M -151M -138M — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -70.4M -77M -108M -170M -161M -145M — — — —
Income detail
Research and development expense (USD) 53.9M 33.9M 27.3M 19.8M 10.4M 7.09M — — — —
↳ 5y CAGR +247.0% +49.8% +15.0% -14.5% -32.1% -33.4%
Total comprehensive income (USD) — — — -176M -184M -172M 112M -10.3M — —
Comprehensive income to owners (USD) — — — -176M -184M -172M 112M -10.3M — —
Provision for credit losses (USD) 2.52M 4,206 216,022 307,438 213,814 533,000 — — — —
Credit cost ratio (credit losses / average receivables) (%) 66.9% 0.1% 2.8% 1.7% 0.8% 1.6% — — — —
Reported Feb 24, 2020 Nov 8, 2019 Nov 8, 2019 Mar 23, 2022 Mar 23, 2022 Mar 23, 2022 Apr 7, 2023 Aug 12, 2024 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BOCA RATON, Fla.--(BUSINESS WIRE)—November 13, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2026.

Third Quarter 2026 Financial Results

Net Income from Continuing Operations

● Net income from continuing operations totaled $501 thousand, or $0.04 per basic and diluted common share, compared to income from continuing operations of $50 thousand, or $0.00 per basic and diluted common share for the third quarter of 2025.

License Revenues from Continuing Operations

● The Company recorded $1.3 million in license revenue for the third quarter of 2026, an increase of $475 thousand, or 60.6%, compared to $784 thousand in license revenue for the third quarter of 2025. The increase is primarily attributable to the achievement of an IMVEXXY sales-based milestone by Knight relating to IMVEXXY sales for the year ended December 31, 2025, resulting in a $365 thousand milestone payment that was recognized and confirmed by Knight in the third quarter of 2026.

BOCA RATON, Fla.--(BUSINESS WIRE)--Aug. 11, 2026-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026.

Second Quarter 2026 Financial Results

Net Income from Continuing Operations

  • Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025.

License Revenues from Continuing Operations

  • The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue for the second quarter of 2025. The decrease is attributable to changes in sales of licensed products.

  • Following the end of the second quarter, Knight Therapeutics Inc. notified the Company that the net sales milestone related to IMVEXXY sales for the year ended December 31, 2025 had been achieved, entitling the Company to a milestone payment of CAD 500 thousand (approximately US $364.8 thousand). The Company will recognize this milestone revenue in the third quarter of 2026 in accordance with its accounting policies.

Total Operating Expenses from Continuing Operations

  • Total operating expenses for the second quarter of 2026 were $1,685 thousand, an increase of $38 thousand, compared to $1,647 thousand for the second quarter of 2025.

Evaluation of Strategic Alternatives

  • The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.

Balance Sheet

  • As of June 30, 2026, the Company’s cash and cash equivalents totaled $9.2 million.

About TherapeuticsMD

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a review process and the potential timing, outcome and ability of any such strategic alternatives to create stockholder value, as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future, including statements regarding the Company’s financial condition, liquidity, results of operations and royalty revenues. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the Company’s licensees will be successful at commercializing the products that they licensed and acquired from TherapeuticsMD; the Company’s dependence upon third parties for the manufacture and supply the Company’s women’s healthcare products; whether coverage and reimbursement is available for the Company’s products; the outcome of the Company’s ongoing disputes with Mayne Pharma; risks related to the pursuit of strategic alternatives, market and general economic factors; the receipt of the IMVEXXY net sales milestone payment; time and costs associated with winding down the Company’s operations; the Company’s ability to remain listed on Nasdaq; the impact of transitions in the Company’s senior management team; the impact of government regulation, including those resulting from healthcare reform and drug pricing initiatives; whether we are able to protect the proprietary nature of the intellectual property covering the Company’s hormone therapy pharmaceutical products; competition from branded and generic products; and the Company’s ability to continue as a going concern.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260811557853/en/

Marlan D. Walker Chief Executive Officer 561-961-1900 [email protected]

Lisa M. Wilson In-Site Communications, Inc. 212-452-2793 [email protected]

Source: TherapeuticsMD, Inc.

PRIMARY TXMD CONTACTS

Lisa M. Wilson In-Site Communications, Inc. 212-452-2793 [email protected] [email protected]

TherapeuticsMD 951 Yamato Road Suite 220 Boca Raton, FL 33431 561-961-1900 or [email protected]

BOCA RATON, Fla.--(BUSINESS WIRE)--May 12, 2026-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026.

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

  • Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

  • The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter of 2025. The increase is attributable to changes in sales of licensed products.

Total Operating Expenses from Continuing Operations

  • Total operating expenses were $1,447 thousand, a decrease of $227 thousand, or 13.6%, compared to $1,674 thousand for the first quarter of 2025. The decrease is primarily attributable to the absence of write-off expense recognized in 2025, as well as lower professional fees and share-based compensation costs.

Evaluation of Strategic Alternatives

  • The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.

Balance Sheet

  • As of March 31, 2026, the Company’s cash and cash equivalents totaled $8.4 million.

About TherapeuticsMD

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a review process and the potential timing, outcome and ability of any such strategic alternatives to create stockholder value, as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future, including statements regarding the Company’s financial condition, liquidity, results of operations and royalty revenues. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the Company’s licensees will be successful at commercializing the products that they licensed and acquired from TherapeuticsMD; the Company’s dependence upon third parties for the manufacture and supply the Company’s women’s healthcare products; whether coverage and reimbursement is available for the Company’s products; the outcome of the Company’s ongoing disputes with Mayne Pharma; time and costs associated with winding down the Company’s operations; the Company’s ability to remain listed on Nasdaq; the impact of transitions in the Company’s senior management team; the impact of government regulation, including those resulting from healthcare reform and drug pricing initiatives; whether we are able to protect the proprietary nature of the intellectual property covering the Company’s hormone therapy pharmaceutical products; competition from branded and generic products; and the Company’s ability to continue as a going concern.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512202804/en/

Marlan D. Walker Chief Executive Officer 561-961-1900 [email protected]

Lisa M. Wilson In-Site Communications, Inc. 212-452-2793 [email protected]

Source: TherapeuticsMD, Inc.

PRIMARY TXMD CONTACTS

Lisa M. Wilson In-Site Communications, Inc. 212-452-2793 [email protected] [email protected]

TherapeuticsMD 951 Yamato Road Suite 220 Boca Raton, FL 33431 561-961-1900 or [email protected]

Prompts

TherapeuticsMD, Inc. (ticker TXMD), listed in United States.

Company History

Date Change Detail
Aug 17, 2011 Renamed AMHN, INC. → THERAPEUTICSMD, INC.
Sep 30, 2009 Renamed CROFF ENTERPRISES INC → AMHN, INC.

ETFs Holding TherapeuticsMD, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 3,612 $ 6,573.84 Nov 12, 2026
DXUV 0.00% 5,063 $ 9,214.66 Nov 12, 2026
DCOR 0.00% 3,076 $ 5,598.32 Nov 12, 2026
DFAC 0.00% 4,826 $ 8,783.32 Nov 12, 2026